Literature DB >> 19592505

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.

Yang Zong1, Li Xin, Andrew S Goldstein, Devon A Lawson, Michael A Teitell, Owen N Witte.   

Abstract

Chromosomal rearrangements involving erythroblast transformation specific (ETS) family transcription factors were recently defined as the most common genetic alterations in human prostate cancer. Despite their prevalence, it is unclear what quantitative role they play in either initiation or progression of the disease. Using a lentiviral transduction and dissociated cell prostate regeneration approach, we find that acutely increased expression of ETS proteins in adult murine prostate epithelial cells is sufficient to induce the formation of epithelial hyperplasia and focal prostatic intraepithelial neoplasia (PIN) lesions, but not progression to carcinoma. However, combined expression of ERG with additional genetic alternations associated with human prostate cancer can lead to aggressive disease. Although ERG overexpression does not cooperate with loss of the tumor suppressor p53, it does collaborate with alterations in PI3K signaling, such as Pten knockdown or AKT up-regulation, to produce a well-differentiated adenocarcinoma. Most striking is our finding that overexpression of androgen receptor (AR) does not give rise to any hyperplastic lesions, but when combined with high levels of ERG, it promotes the development of a more poorly differentiated, invasive adenocarcinoma. These findings suggest that in human prostate cancer, the most potent function of ETS gene fusions may be to synergize with alternative genetic events and provide different pathways for carcinoma production and invasive behavior. Our results provide direct evidence for selective cooperating events in ERG-induced prostate tumorigenesis and offer a rational basis for combined therapeutic interventions against multiple oncogenic pathways in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19592505      PMCID: PMC2708977          DOI: 10.1073/pnas.0905931106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Saravana M Dhanasekaran; Beth E Helgeson; Xuhong Cao; David S Morris; Anjana Menon; Xiaojun Jing; Qi Cao; Bo Han; Jindan Yu; Lei Wang; James E Montie; Mark A Rubin; Kenneth J Pienta; Diane Roulston; Rajal B Shah; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Nature       Date:  2007-08-02       Impact factor: 49.962

2.  Isolation and functional characterization of murine prostate stem cells.

Authors:  Devon A Lawson; Li Xin; Rita U Lukacs; Donghui Cheng; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

3.  Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

Authors:  J-M Mosquera; S Perner; F Demichelis; R Kim; M D Hofer; K D Mertz; P L Paris; J Simko; C Collins; T A Bismar; A M Chinnaiyan; M A Rubin
Journal:  J Pathol       Date:  2007-05       Impact factor: 7.996

4.  TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.

Authors:  Karin G Hermans; Ronald van Marion; Herman van Dekken; Guido Jenster; Wytske M van Weerden; Jan Trapman
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

5.  Role of the TMPRSS2-ERG gene fusion in prostate cancer.

Authors:  Scott A Tomlins; Bharathi Laxman; Sooryanarayana Varambally; Xuhong Cao; Jindan Yu; Beth E Helgeson; Qi Cao; John R Prensner; Mark A Rubin; Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

6.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Authors:  Beth E Helgeson; Scott A Tomlins; Nameeta Shah; Bharathi Laxman; Qi Cao; John R Prensner; Xuhong Cao; Nirmish Singla; James E Montie; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

7.  A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity.

Authors:  Joseph R Garlich; Pradip De; Nandini Dey; Jing Dong Su; Xiaodong Peng; Antoinette Miller; Ravoori Murali; Yiling Lu; Gordon B Mills; Vikas Kundra; H-K Shu; Qiong Peng; Donald L Durden
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

8.  A causal role for ERG in neoplastic transformation of prostate epithelium.

Authors:  Olga Klezovitch; Michael Risk; Ilsa Coleman; Jared M Lucas; Manda Null; Lawrence D True; Peter S Nelson; Valeri Vasioukhin
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-01       Impact factor: 11.205

9.  c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer.

Authors:  Changmeng Cai; Chen-Lin Hsieh; Lirim Shemshedini
Journal:  Mol Cancer Res       Date:  2007-07       Impact factor: 5.852

10.  Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.

Authors:  Sanaz Memarzadeh; Li Xin; David J Mulholland; Alka Mansukhani; Hong Wu; Michael A Teitell; Owen N Witte
Journal:  Cancer Cell       Date:  2007-12       Impact factor: 31.743

View more
  112 in total

1.  Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.

Authors:  Wendell S Fortson; Shubhalaxmi Kayarthodi; Yasuo Fujimura; Huali Xu; Roland Matthews; William E Grizzle; Veena N Rao; Ganapathy K Bhat; E Shyam P Reddy
Journal:  Int J Oncol       Date:  2011-04-21       Impact factor: 5.650

2.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

Review 3.  Embryonic stem cell-specific signature in cervical cancer.

Authors:  Jorge Organista-Nava; Yazmín Gómez-Gómez; Patricio Gariglio
Journal:  Tumour Biol       Date:  2013-10-28

4.  An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Authors:  Jindan Yu; Jianjun Yu; Ram-Shankar Mani; Qi Cao; Chad J Brenner; Xuhong Cao; Xiaoju Wang; Longtao Wu; James Li; Ming Hu; Yusong Gong; Hong Cheng; Bharathi Laxman; Adaikkalam Vellaichamy; Sunita Shankar; Yong Li; Saravana M Dhanasekaran; Roger Morey; Terrence Barrette; Robert J Lonigro; Scott A Tomlins; Sooryanarayana Varambally; Zhaohui S Qin; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

5.  Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells.

Authors:  Peter C Hollenhorst; Mary W Ferris; Megan A Hull; Heejoon Chae; Sun Kim; Barbara J Graves
Journal:  Genes Dev       Date:  2011-10-15       Impact factor: 11.361

Review 6.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

Review 7.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

8.  ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.

Authors:  Changmeng Cai; Hongyun Wang; Housheng Hansen He; Sen Chen; Lingfeng He; Fen Ma; Lorelei Mucci; Qianben Wang; Christopher Fiore; Adam G Sowalsky; Massimo Loda; X Shirley Liu; Myles Brown; Steven P Balk; Xin Yuan
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

9.  Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.

Authors:  Scott A Tomlins; Nallasivam Palanisamy; Javed Siddiqui; Arul M Chinnaiyan; Lakshmi P Kunju
Journal:  Arch Pathol Lab Med       Date:  2012-08       Impact factor: 5.534

10.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.